logo
Plus   Neg
Share
Email

Agilent: FDA Approves Expanded Use Of PD-L1 IHC 28-8 PharmDx - Quick Facts

Agilent Technologies Inc. (A) announced the FDA has approved the company's PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer. This will authorize the use of PD-L1 IHC 28-8 pharmDx assay as an aid in identifying patients with metastatic NSCLC for treatment with the dual immunotherapy combination of Opdivo and Yervoy,
manufactured by Bristol Myers Squibb.

"The expanded use of PD-L1 IHC 28-8 pharmDx will give physicians in the USA critical information to inform first-line treatment decisions for patients with metastatic non-small cell lung cancer," said Sam Raha, president of Agilent's Diagnostics and Genomics Group.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test. Oracle and Walmart have tentatively agreed to acquire 20% of the newly formed TikTok Global business, the companies said in a statement.
RELATED NEWS
Follow RTT